Syndromes Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Syndromes stocks.

Syndromes Stocks Recent News

Date Stock Title
Sep 30 REGN Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30 OVID Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
Sep 29 REGN Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Sep 29 REGN Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
Sep 29 REGN Regeneron: Long-Term Defensive Investment
Sep 28 REGN Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 28 REGN Wall Street Breakfast: What Moved Markets
Sep 28 REGN Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
Sep 27 REGN Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 REGN Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Sep 27 REGN FDA greenlights Regeneron’s Dupixent for the treatment of COPD
Sep 27 REGN Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 REGN Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 REGN Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 REGN Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 REGN Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Sep 27 REGN Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Sep 27 ALMS Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Sep 27 REGN Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Sep 27 REGN FDA, after delay, clears Regeneron and Sanofi drug for COPD
Syndromes

A syndrome is a set of medical signs and symptoms that are correlated with each other and, often, with a particular disease or disorder. The word derives from the Greek σύνδρομον, meaning "concurrence". In some instances, a syndrome is so closely linked with a pathogenesis or cause that the words syndrome, disease, and disorder end up being used interchangeably for them. This is especially true of inherited syndromes. For example, Down syndrome, Wolf–Hirschhorn syndrome, and Andersen syndrome are disorders with known pathogeneses, so each is more than just a set of signs and symptoms, despite the syndrome nomenclature. In other instances, a syndrome is not specific to only one disease. For example, toxic shock syndrome can be caused by various toxins; premotor syndrome can be caused by various brain lesions; and premenstrual syndrome is not a disease but simply a set of symptoms.
If an underlying genetic cause is suspected but not known, a condition may be referred to as a genetic association (often just "association" in context). By definition, an association indicates that the collection of signs and symptoms occurs in combination more frequently than would be likely by chance alone.Syndromes are often named after the physician or group of physicians that discovered them or initially described the full clinical picture. Such eponymous syndrome names are examples of medical eponyms. Recently, there has been a shift towards naming conditions descriptively (by symptoms or underlying cause) rather than eponymously, but the eponymous syndrome names often persist in common usage.

Browse All Tags